Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan in severe chronic kidney disease with congestive heart failure
jRCTs031180158Completed
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tolvaptan in chronic kidney disease (CKD) and heart failure (HF). Primary endpoint: Transition rate to eGFR < 6 mL/min/1.73 m² within one year. Started Nov 2018; status: completed.
02
Drugs
tolvaptan
03
Conditions
chronic kidney disease (CKD)heart failure (HF)
Beyond the preview
Go deeper on jRCTs031180158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180158.